What you should know:
– Biotech Company Phenomix . Science Launched its biobanking registry, marking the first obesity registry to study the impact of personalized treatment based on Phenotype. The impact of the biobank track record and the data it will result in has the potential to change the entire system’s approach to obesity, from treatment recommendation to the way payers define coverage and how the industry combines diagnostic testing with drug therapy.
The data collected will complement the 20 billion unique data points that make up the Phenomix Sciences obesity platform. Mayo Clinic She is the first to go on the registry with the Rochester site set to contribute patient outcomes from 2,000 patients undergoing obesity treatment to her biobank.
Understanding the phenotype
Phenotyping is a new method for treating obesity and 5, a biotechnology company, is the first to bring this technology to the market with proven results. Announcing the company’s biobank is the next step to collect real data on patients to better understand phenotypes by looking at patients’ DNA, metabolism, hormones, patient behavior, evaluations, and treatment outcomes. A growing body of evidence indicates that obesity is not a single disease with a single therapeutic type, but rather a group of diseases.
The roots of obesity lie in individual DNA. However, evidence suggests that there is a complex network linking obesity with age, race, gender, education, and socioeconomic status. Understanding a person’s obesity phenotype — a combination of genes with environmental and behavioral factors — can help determine the cause of weight gain. Phenomix phenotypes are based on research from Founding Physicians, Andres Acosta, MD, Ph.D. and Michael Camilleri, MD, of the Mayo Clinic, who has shown that when patients are phenotyped and appropriate medications prescribed, they can achieve up to 16 percent of total body weight loss (TBWL).
How Obesity Biobanking Registry Works
Outcome data generated from biobanks via the registry will complement the Phenomix database of biological and clinical data matched with Four obesity phenotypes. The insights generated from the database are used to develop more predictive tests to determine the correct intervention for each obese patient. This will allow for a better understanding of the variance in patients’ outcomes when undergoing obesity treatments. Despite justified excitement about new weight management products such as semaglutide and tirzepatide, several clinical studies from the founders of Phenomix indicate that patient response varies depending on the underlying phenotype. Thus, for many patients, it will open the door to the most effective and appropriate intervention for their unique phenotype.
The registry will complete the 20 billion unique data points that already make up the Phenomix Sciences Obesity Platform and Mayo ClinicThe Rochester site is the first center of excellence to be on the registry, with plans to contribute patient outcomes from 2,000 patients undergoing bariatric treatment to its biobank.
This record and the data it will result in has the potential to dramatically change approaches to obesity treatment, including the way obesity payers define coverage and how the industry combines diagnostic testing with drug therapy.
“This unique biobank registry will provide important, contemporary data on obesity outcomes, impacting all stakeholders in the care loop,” said Mark Bagnall, CEO of Phenomix Sciences. “This registry is an important opportunity to make strides in how we understand the complexities of obesity treatment. All obesity programs should look for an opportunity to participate and contribute to this registry. The more data we have on variables that contribute to an individual’s obesity diagnosis, the more lives we can save.” Save it by putting the best treatment plan ahead.We believe investing in a biobank registry will better support obesity centers by providing tangible evidence and insight into how DNA and other factors need to be considered in treatment.Patients can benefit greatly from achieving the desired outcome this time First, advocates avoid paying for trial and error approaches and can reduce members’ co-morbid conditions.”